GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Icecure Medical Ltd (NAS:ICCM) » Definitions » EV-to-Revenue

Icecure Medical (Icecure Medical) EV-to-Revenue : 13.33 (As of May. 10, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Icecure Medical EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Icecure Medical's enterprise value is $43.04 Mil. Icecure Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $3.23 Mil. Therefore, Icecure Medical's EV-to-Revenue for today is 13.33.

The historical rank and industry rank for Icecure Medical's EV-to-Revenue or its related term are showing as below:

ICCM' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.32   Med: 14.69   Max: 184.87
Current: 13.47

During the past 11 years, the highest EV-to-Revenue of Icecure Medical was 184.87. The lowest was 5.32. And the median was 14.69.

ICCM's EV-to-Revenue is ranked worse than
85.21% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: 3.21 vs ICCM: 13.47

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-10), Icecure Medical's stock price is $1.18. Icecure Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07. Therefore, Icecure Medical's PS Ratio for today is 16.62.


Icecure Medical EV-to-Revenue Historical Data

The historical data trend for Icecure Medical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icecure Medical EV-to-Revenue Chart

Icecure Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.44 9.64 20.40 15.45 11.91

Icecure Medical Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.45 15.56 15.68 7.36 11.91

Competitive Comparison of Icecure Medical's EV-to-Revenue

For the Medical Devices subindustry, Icecure Medical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icecure Medical's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Icecure Medical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Icecure Medical's EV-to-Revenue falls into.



Icecure Medical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Icecure Medical's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=43.041/3.229
=13.33

Icecure Medical's current Enterprise Value is $43.04 Mil.
Icecure Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Icecure Medical  (NAS:ICCM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Icecure Medical's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.18/0.071
=16.62

Icecure Medical's share price for today is $1.18.
Icecure Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Icecure Medical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Icecure Medical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Icecure Medical (Icecure Medical) Business Description

Traded in Other Exchanges
N/A
Address
7 Haeshel Street, Southern Industrial Park, PO Box 3163, Caesarea, ISR, 3079504
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.